Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey
- PMID: 18847180
Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey
Abstract
Over a three years period, 472 Candida isolates were obtained from specimens of patients hospitalized either in "at risk", Bone Marrow Transplant Unit and Intensive Care Unit, or in conventional wards, Pneumological Divisions of the "Binaghi" Hospital of Cagliari (Italy). Antifungal susceptibility profile to amphotericin B, voriconazole, fluconazole and ketoconazole was determined. Candida albicans was the predominant species while Candida krusei was the most frequent non-albicans species. C. krusei was significantly more common among Bone Marrow Transplant Unit and Intensive Care Unit than Pneumological Divisions patients (17.9% and 14.1% vs. 6.0%; p < 0.05). No significant differences were observed when the same distribution was analysed with regard to the other Candida species or when Bone Marrow Transplant Unit and Intensive Care Unit were compared. The profiles of susceptibility to the antifungal drugs among isolates from the different hospital wards showed no significant differences, even though most of MIC values were higher for Intensive Care Unit isolates compared to those for Bone Marrow Transplant Unit and Pneumological Divisions. For C. albicans isolates, amphotericin B was the more efficient antifungal (97.7% S), while fluconazole (6.1% R [Resistant] and 2.6% SDD [Susceptible Dose Dependent]) and ketoconazole (4.1% R and 3.2% SDD) showed the lowest activity. Voriconazole was the more efficient antimycotic for C. krusei (96.7% S) and Candida glabrata (100% S [Sensible]) isolates. This study has shown a significantly higher presence of non-albicans Candida in at risk wards as well as a decreased susceptibility to the older azoles (ketoconazole and fluconazole) among C. albicans isolates.
Similar articles
-
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.J Hosp Infect. 2002 Apr;50(4):243-60. doi: 10.1053/jhin.2001.1151. J Hosp Infect. 2002. PMID: 12014897 Review.
-
Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period.Mycoses. 2007 Jan;50(1):52-7. doi: 10.1111/j.1439-0507.2006.01309.x. Mycoses. 2007. PMID: 17302749
-
Susceptibility patterns of Candida species recovered from Canadian intensive care units.J Crit Care. 2007 Sep;22(3):245-50. doi: 10.1016/j.jcrc.2006.10.038. Epub 2007 Jan 31. J Crit Care. 2007. PMID: 17869976
-
Molecular epidemiology of Candida species isolated from urine at an intensive care unit.Mycoses. 2005 Mar;48(2):126-31. doi: 10.1111/j.1439-0507.2004.01086.x. Mycoses. 2005. PMID: 15743431
-
Update on clinical antifungal susceptibility testing for Candida species.Pharmacotherapy. 1998 May-Jun;18(3):509-15. Pharmacotherapy. 1998. PMID: 9620102 Review.
Cited by
-
Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients.BMC Infect Dis. 2011 May 17;11:130. doi: 10.1186/1471-2334-11-130. BMC Infect Dis. 2011. PMID: 21586108 Free PMC article.
-
Evaluation of saliva flow rates, Candida colonization and susceptibility of Candida strains after head and neck radiation.Clin Oral Investig. 2012 Aug;16(4):1305-12. doi: 10.1007/s00784-011-0612-1. Epub 2011 Sep 9. Clin Oral Investig. 2012. PMID: 21904917
-
Correlation between antifungal consumption and the distribution of Candida species in different hospital departments of a Lebanese medical Centre.BMC Infect Dis. 2018 Nov 20;18(1):589. doi: 10.1186/s12879-018-3512-z. BMC Infect Dis. 2018. PMID: 30453891 Free PMC article.
-
Antimicrobial activity of Buchenavia tetraphylla against Candida albicans strains isolated from vaginal secretions.Pharm Biol. 2017 Dec;55(1):1521-1527. doi: 10.1080/13880209.2017.1304427. Pharm Biol. 2017. PMID: 28376640 Free PMC article.
-
The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future.Front Immunol. 2018 Apr 27;9:897. doi: 10.3389/fimmu.2018.00897. eCollection 2018. Front Immunol. 2018. PMID: 29755472 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical